Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025413 · ClinicalTrials.gov registry record · NA
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02025413: Completed NA study, sponsored by Duke University.
NCT02025413 is a NA study that has completed, run by Duke University. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02025413, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based). The primary objective of each comparative cohort (second stage, prostate cancer) is to compare the non-detection rate of circulating tumor cells between the standard and novel methods.
Interventions
- DEVICE Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02025413 record still lists
NCT02025413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based) is the first listed.
NCT02025413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02025413 about?
NCT02025413 is a clinical study titled "Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method". The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or...
What is the current status of trial NCT02025413?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02025413?
The interventions under investigation include: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based) (DEVICE).
Who is sponsoring clinical trial NCT02025413?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02025413's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia